Home › NCT07282782

Vancomycin in TKAs

A Prospective, Randomized Parallel Group Study of the Efficacy of Vancomycin Administered Through Intraarticular Injection Versus Intraosseous Injection Versus Intravenous Infusion in Patients Undergoing Total Knee Arthroplasty

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Any patient over the age of 18 years of age receiving treatment at UC San Diego Health
* Undergoing primary unilateral TKA
* Ability to provide consent

Exclusion Criteria:

* previous surgery on the knee (with the exception of arthroscopy)
* BMI \> 35
* contraindication to receiving vancomycin, cefepime or cefazolin (ie, allergy, etc)
* diabetics with A1c\>7.5% (unless controlled fructosamine)
* immunocompromised or immunosuppressed patients (HIV, Hepatitis C, end stage renal disease (ESRD), post transplant, chemotherapy or radiation therapy within 6 months of surgery, immunomodulating meducations)
* no history of active infections
* no history of chronic kidney disease

About the study

Periprosthetic joint infection (PJI) is a national health crisis and leads to very poor outcomes for patients undergoing elective joint replacement. Within the realm of elective total knee arthroplasty (TKA), various methods of infection prophylaxis are in place. These include sterile precautions, would/tissue handling, and antibiotic prophylaxis. With respect to the latter, various approaches have been utilized including intravenous and intraosseous administration of vancomycin, preoperatively. Intraosseous administration does require another wound and a specific device to administer. The investigators proposed that intraarticular injection of vancomycin is non-inferior to intraosseous administration, thus reducing wounds, time, and cost.

What is being tested

• Vancomycin (drug)

Sponsor: University of California, San Diego · Participants: 30 · Started: Jun 10, 2024

Contact the study team

• Dominic Baun · Phone: 858-534-8268

Official record on ClinicalTrials.gov — NCT07282782

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.